Glenmark secures exclusive global rights (excluding specified regions) for Hengrui's ADC Trastuzumab Rezetecan in partnership.

• Upfront payment of US$18 million granted to Hengrui, initiating the exclusive licensing agreement for Glenmark's development.
• Hengrui is eligible for regulatory and commercial milestones totaling up to US$1.093 billion during the development of Trastuzumab.
• Glenmark will remit royalties to Hengrui, calculated from net sales within the licensed territories globally.